Related Experiment Video
Updated: Jun 25, 2026

Identification of EcoHIV-Infected Cells in Microglia-Manipulated Transgenic Mice
Published on: December 20, 2024
Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy
Deanna Cettomai1, Justin C McArthur
1Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Background:
An efficacious treatment is needed for human immunodeficiency virus (HIV)-infected and uninfected patients with progressive multifocal leukoencephalopathy (PML).
Objective:
To report clinical and magnetic resonance imaging changes in response to mirtazapine treatment in HIV-positive patients with PML.
Design:
Case series.
Setting:
Outpatient neurology clinic.
Patients:
Four HIV-positive patients with PML.
Interventions:
Mirtazapine use, 15 mg nightly.
Main Outcome Measures:
Neurologic examinations and cranial magnetic resonance imaging.
Results:
Three patients demonstrated objective clinical improvement, and 1 patient showed improvement on magnetic resonance imaging. The patient who experienced the most significant clinical improvement was the patient who received mirtazapine therapy closest to PML symptom onset. Mirtazapine use was safe and well tolerated.
Conclusion:
Mirtazapine use may offer some benefit as treatment or prophylaxis for PML in patients with HIV infection.
Insights
Mirtazapine shows promise for treating progressive multifocal leukoencephalopathy (PML) in HIV patients. Three of four patients experienced clinical improvement, with early treatment yielding the best results.
Area of Science:
- Neurovirology
- Clinical Neurology
- Pharmacology
Background:
- Progressive multifocal leukoencephalopathy (PML) is a serious opportunistic infection in human immunodeficiency virus (HIV)-positive individuals.
- There is a critical need for effective treatments for PML, particularly in the context of HIV infection.
Observation:
- This study presents a case series of four HIV-positive patients diagnosed with PML.
- The patients received mirtazapine, an antidepressant, at a dosage of 15 mg nightly as a potential therapeutic intervention.
Findings:
- Three out of the four patients exhibited objective clinical improvement following mirtazapine treatment.
- One patient demonstrated positive changes on cranial magnetic resonance imaging (MRI).
- The most substantial clinical benefit was observed in the patient treated earliest after PML symptom onset.
Implications:
- Mirtazapine may serve as a beneficial treatment or prophylactic agent for PML in individuals with HIV.
- Further research is warranted to confirm the efficacy and optimal use of mirtazapine in managing PML.
Related Concept Videos
Cryptococcal Meningitis
Antiprotozoal Agents
Leishmaniasis
Antidepressant Drugs: MAOIs and Other Agents
Psychosis: Goals of Pharmacotherapy
Retrovirus Life Cycles

